Objective This study was aimed to investigate the efficacy and safety of low-dose decitabine combined with G-HA regimen in treatment for patients with high-risk myelodysplastic syndrome(MDS).Methods 24 newly diagnosed adult patients with high-risk MDS were enrolled in the low-dose decitabine combined with G-HA regimen,which consisted of decitabine,10 mg,intravenous continuous infusion,days 1-5.GHA regimen consisted of homoharringtonine1mg/day by intravenous continuous infusion,days 1-14,cytarabine 10mg/12 hr by subcutaneous injection,days 1-14,and G-csf 300mg/day by subcutaneous injection,one day prior to chemotherapy and continued until the end of chemotherapy or when the peripheral WBC>20×109/L.The clinical efficiency and side effects were observed.Results 16 patients achieved CR and 3patients achieved PR.The CR and PR rate were 66.7% and 12.5%,respectively.Total effective rate was 79.2%.In the induction therapy,18patients(75.0%)experienced absolute neutrophol count(ANC)less than 0.5×10~9/L with a mean 8days of agranulocytic period,and 17patients(70.8%)experienced platelets less than20×109/L with a mean 7days of recovery over 20×109/L.The nonhematologic toxicities were mild and early death was zero.The median follow up time was 28months;the median overall survival(OS)and disease free survival(DFS)were26and 13 months,respectively.Conclusion The low-dose decitabine combined with G-HA regimen is effective and well tolerated in induction therapy for high-risk MDS,and the results are better than the single regimen of decitabine or G-HA. 更多